An interventional study of Non-invasive pelvic floor neuromuscular stimulation in Urinary Incontinence and Prostatectomy, sponsored by University of California, Los Angeles. Enrolling by invitation at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies in Urinary Incontinence with a site in United States — 33 open to participants now, 47 under way, 3 of them phase 3. Urinary Incontinence · United States.
Among the 293 studies in Urinary Incontinence with a site in United States, this one is the 165th largest by planned enrollment of the 249 interventional ones that give a count, is one of 11 that started in 2026, is one of 144 with no phase, reaches primary completion later than 18 of the 46 other live ones, and was the 288th registered.
988 studies on the registry are indexed under Urinary Incontinence; 184 are open to participants now.
Browse Urinary Incontinence studies →33 of the 293 studies in Urinary Incontinence with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada
Ages 18+ · Women only
Duke University · Sites in United States
Ages 18+ · Men only
Ohio State University · Sites in United States
Ages 18+ · Women only
The Methodist Hospital Research Institute · Sites in United States
Ages 22–80 · Men only · Healthy volunteers
University of Miami · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 113 Urinary Incontinence studies recruiting now, 63 (56%) set no upper age limit and 35 (31%) stop at 75 or younger; 15 take children under 18; 28 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 23 · Phase 3 38 · Phase 4 35
First in 1993; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 37 is below the median of 66 across 743 interventional studies indexed under Urinary Incontinence.
Median enrollment 75 across the 249 interventional studies, 100 across the 43 observational. Of the 219 that completed or were terminated, 105 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 293 have an industry lead sponsor. The 10 most frequent:
University of California, Los Angeles is the lead sponsor of 1,172 studies on the registry; 195 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.
University of California, Los Angeles has 1 study filed under Urinary Incontinence — fewer than ten, so there is no comparison to draw.
16 of the studies in Urinary Incontinence with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387315TriHealth Inc.A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections | 2026-11 |
| NCT04565925The University of Texas Medical Branch, GalvestonSildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries | 2026-12-01 |
| NCT07534696University of California, Los AngelesEvaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy | 2026-12-31 |
| NCT06226220University of ChicagoPercutaneous Nerve Evaluation Trial Time | 2026-12-31 |
| NCT06369922University of RochesterTENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence. | 2027-01-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 293 studies in Urinary Incontinence with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Urinary incontinence is a common complication following prostatectomy and affects a substantial proportion of patients. Despite advances in surgical technique, many patients experience persistent symptoms that negatively impact quality of life. Current management strategies include pelvic floor muscle training, biofeedback and physical therapy, and surgical options. However, these approaches may be limited by adherence, access, and invasiveness, leaving a subset of patients with ongoing symptoms despite standard care.
Non-invasive pelvic floor neuromuscular stimulation has emerged as a potential adjunct for pelvic floor rehabilitation by inducing supramaximal muscle contractions and enhancing neuromuscular activation without requiring active patient effort. Preliminary studies suggest that high-intensity electromagnetic stimulation may improve patient-reported continence outcomes and pad usage in women as well as men following radical prostatectomy, though existing data are limited by small sample sizes and short follow-up durations. Additionally, no clinical studies exist evaluating outcomes in men following prostatectomy prior to established stress incontinence.
Given these limitations, further evaluation is needed to assess the feasibility, tolerability, and short-term effectiveness of this intervention in a post-prostatectomy population.
This prospective study aims to evaluate feasibility, safety, and patient-reported continence outcomes associated with non-invasive pelvic floor neuromuscular stimulation in men with urinary incontinence following prostatectomy. Findings may inform future clinical implementation and guide the design of larger, controlled trials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will complete an 8-week intervention (12 sessions total) of non-invasive pelvic floor neuromuscular stimulation, with outcomes assessed at baseline, end of treatment, and follow-up within three months of starting the intervention.
Device: Non-invasive pelvic floor neuromuscular stimulation
Participants will complete an 8-week intervention (12 sessions total), with outcomes assessed at baseline, end of treatment, and follow-up within three months of starting the intervention.
Change in EPIC questionnaire score
The Expanded Prostate Cancer Index Composite (EPIC) is a validated questionnaire assessing urinary, bowel, sexual, and hormonal outcomes.
Time frame: From enrollment to 3 months after initiation of treatment
Change in ICIQ-UI questionnaire score
The International Consultation on Incontinence Questionnaire Urinary Incontinence (ICIQ-UI) short form is a validated questionnaire assessing urinary incontinence.
Time frame: From enrollment to 3 months after initiation of treatment
Continence
Continence is measured by number of pads used per 24 hours, with continence defined as less than one pad used per day.
Time frame: From enrollment to 3 months after initiation of treatment
Treatment failure
Treatment failure is defined as requiring procedural or surgical intervention for urinary incontinence following prostatectomy.
Time frame: From enrollment to 3 months after initiation of treatment
Plan to share: No
Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.
Of 303 non-industry interventional studies with no phase under Urinary Incontinence, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 7 months is below that.
Counting every sponsor, half of 366 studies reached it within 15 months; a quarter within 7 and three quarters within 34.
Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Oct 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Los Angeles →